SEARCH

SEARCH BY CITATION

References

  • Ader, I., Brizuela, L., Bouquerel, P., Malavaud, B., and Cuvillier, O. (2008). Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res. 68, 86358642.
  • Antoon, J.W., Meacham, W.D., Bratton, M.R., Slaughter, E.M., Rhodes, L.V., Ashe, H.B., Wiese, T.E., Burow, M.E., and Beckman, B.S. (2011). Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. J. Mol. Endocrinol. 28, 205216.
  • Aplin, A.E., Kaplan, F.M., and Shao, Y. (2011). Mechanism of resistance to RAF inhibitors in melanoma. J. Invest. Dermatol. 131, 18171820.
  • Bektas, M., Jolly, P.S., Muller, C., Eberle, J., Spiegel, S., and Geilen, C.C. (2005). Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene 24, 178187.
  • Beljanski, V., Knaak, C., Zhuang, Y., and Smith, C.D. (2011). Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest. New Drugs 29, 11321142.
  • Cheung, M., Sharma, A., Madhunapantula, S.V., and Robertson, G.P. (2008). Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res. 68, 34293439.
  • Edsall, L.C., Cuvillier, O., Twitty, S., Spiegel, S., and Milstien, S. (2001). Sphingosine kinase expression regulates apoptosis and caspase activation in PC12 cells. J. Neurochem. 76, 15731584.
  • Ernst, D.S., Eisenhauer, E., Walnman, N., Davis, M., Lohmann, R., Baetz, T., Belanger, K., and Smylie, M. (2005). Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest. New Drugs 23, 569575.
  • Flaherty, K.T., Puzanov, K., Kim, K.B. et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809819.
  • Francy, J.M., Nag, A., Conroy, E.J., Hengst, J.A., and Yun, J.K. (2007). Sphingosine kinase 1 expression is regulated by signaling through PI3K, AKT2, and mTOR in human coronary artery smooth muscle cells. Biochim. Biophys. Acta. 1769, 253265.
  • French, K.J., Schrecengost, R.S., Lee, B.D., Zhuang, Y., Smith, S.N., Eberly, J.L., Yun, J.K., and Smith, C.D. (2003). Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 63, 59625969.
  • French, K.J., Upson, J.J., Keller, S.N., Zhuang, Y., Yun, J.K., and Smith, C.D. (2006). Antitumor activity of sphingosine kinase inhibitors. J. Pharmacol. Exp. Ther. 318, 596603.
  • Guan, H., Song, L., Cai, J., Huang, Y., Wu, J., Yuan, J., Li, J., and Li, M. (2011). Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim pathway and contributes to apoptosis resistance in glioma cells. PLoS One 6, e19946.
  • Guo, D., Ye, J., Dai, J., Li, L., Chen, F., Ma, D., and Ji, C. (2008). Notch-1 regulates Akt signaling pathway and the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 in T-ALL cell lines. Leuk. Res. 33, 678685.
  • Hait, N.C., Oskeritzian, C.A., Paugh, S.W., Milstien, S., and Spiegel, S. (2006). Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim. Biophys. Acta 1758, 20162026.
  • Han, W.S., Yoo, J.Y., Youn, S.W., Kim, D.S., Park, K.C., Kim, S.Y., and Kim, K.H. (2002). Effects of C2-ceramide on the Malme-3M melanoma cell line. J. Dermatol. Sci. 30, 1019.
  • Hengst, J.A., Guilford, J.M., Conroy, E.J., Wang, X., and Yun, J.K. (2010a). Enhancement of sphingosine kinase 1 catalytic activity by deletion of 21 amino acids from the COOH-terminus. Arch. Biochem. Biophys. 494, 2331.
  • Hengst, J.A., Wang, X., Sk, U.H., Sharma, A.K., Amin, S., and Yun, J.K. (2010b). Development of a sphingosine kinase 1 specific small-molecule inhibitor. Bioorg. Med. Chem. Lett. 20, 74987502.
  • Hingorani, S.R., Jacobetz, M.A., Robertson, G.P., Herlyn, M., and Tuveson, D.A. (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63, 51985202.
  • Hocker, T.L., Singh, M.K., and Tsao, H. (2008). Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J. Invest. Dermatol. 128, 25752595.
  • Huwiler, A., and Zangemeister-Wittke, U. (2007). Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Crit. Rev. Oncol. Hematol. 63, 150159.
  • Inamdar, G.S., Madhunapantula, S.V., and Robertson, G.P. (2010). Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem. Pharmacol. 80, 624637.
  • Kapitonov, D., Allegood, J.C., Mitchell, C. et al. (2009). Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res. 69, 69156923.
  • Lavieu, G., Scarlatti, F., Sala, G., Carpentier, S., Levade, T., Ghidoni, R., Botti, J., and Codogno, P. (2006). Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation. J. Biol. Chem. 281, 85188527.
  • Leclercq, T.M., and Pitson, S.M. (2006). Cellular signalling by sphingosine kinase and sphingosine 1-phosphate. IUBMB Life 58, 467472.
  • Lee, J.T., Li, L., Brafford, P.A. et al. (2010). PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res. 23, 820827.
  • Leroux, M.E., Auzenne, E., Evans, R., Hail Jr, N., Spohn, W., Ghosh, S.C., Farquhar, D., McDonnell, T., and Klostergaard, J. (2007). Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells. Prostate 67, 16991717.
  • Li, W., Yu, C.P., Xia, J.T. et al. (2009). Phingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin. Cancer Res. 15, 13931399.
  • Madhunapantula, S.V., and Robertson, G.P. (2008). Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res. 68, 58.
  • Madhunapantula, S.V., and Robertson, G.P. (2009). The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 22, 400419.
  • Madhunapantula, S.V., Sharma, A., and Robertson, G.P. (2007). PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res. 67, 36263636.
  • Madhunapantula, S.V., Desai, D., Sharma, A., Huh, S.J., Amin, S., and Robertson, G.P. (2008). PBISe, a novel selenium-containing drug for the treatment of malignant melanoma. Mol. Cancer Ther. 7, 12971308.
  • Melendez, A.J., Carlos-Dias, E., Gosink, M., Allen, J.M., and Takacs, L. (2000). Human sphingosine kinase: molecular cloning, functional characterization and tissue distribution. Gene 251, 1926.
  • Miller, A.V., Alvarez, S.E., Spiegel, S., and Lebman, D.A. (2008). Sphingosine kinases and sphingosine-1-phosphate are critical for transforming growth factor beta-induced extracellular signal-regulated kinase 1 and 2 activation and promotion of migration and invasion of esophageal cancer cells. Mol. Cell. Biol. 28, 41424151.
  • Nava, V.E., Hobson, J.P., Murthy, S., Milstien, S., and Spiegel, S. (2002). Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp. Cell Res. 281, 115127.
  • Nemoto, S., Nakamura, M., Osawa, Y. et al. (2009). Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation. J. Biol. Chem. 284, 1042210432.
  • Nogueira, C., Kim, K.H., Sung, H., Paraiso, K.H., Dannenberg, J.H., Bosenberg, M., Chin, L., and Kim, M. (2010). Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 29, 62226232.
  • Olivera, A., Kohama, T., Edsall, L., Nava, V., Cuvillier, O., Poulton, S., and Spiegel, S. (1999). Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J. Cell Biol. 147, 545558.
  • Pchejetski, D., Doumerc, N., Golzio, M., Naymark, M., Teissie, J., Kohama, T., Waxman, J., Malavaud, B., and Cuvillier, O. (2008). Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol. Cancer Ther. 7, 18361845.
  • Pitson, S.M. (2011). Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem. Sci. 36, 97107.
  • Pitson, S.M., Xia, P., Leclercq, T.M., Moretti, P.A., Zebol, J.R., Lynn, H.E., Wattenberg, B.W., and Vadas, M.A. (2005). Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J. Exp. Med. 201, 4954.
  • Ren, S., Xin, C., Pfeilschifter, J., and Huwiler, A. (2010). A novel mode of action of the putative sphingosine kinase inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole (SKI II): induction of lysosomal sphingosine kinase 1 degradation. Cell Physiol. Biochem. 26, 97104.
  • Robertson, G.P. (2005). Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev. 24, 273285.
  • Sarkar, S., Maceyka, M., Hait, N.C., Paugh, S.W., Sankala, H., Milstien, S., and Spiegel, S. (2005). Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. FEBS Lett. 579, 53135317.
  • Schadendorf, D., Flchtner, I., Makki, A., Alljagic, S., Kupper, M., Mrowletz, U., and Henz, B.M. (1996). Metastatic potential of human melanoma cells in nude mice-characterization of phenotype, cytokine-secretion and tumor-associated antigens. Br. J. Cancer 74, 194199.
  • Schnitzer, S.E., Weigert, A., Zhou, J., and Brune, B. (2009). Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells. Mol. Cancer Res. 7, 393401.
  • Sharma, A., Trivedi, N.R., Zimmerman, M.A., Tuveson, D.A., Smith, C.D., and Robertson, G.P. (2005). Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 65, 24122421.
  • Sharma, A., Tran, M.A., Liang, S., Sharma, A.K., Amin, S., Smith, C.D., Dong, C., and Robertson, G.P. (2006). Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res. 66, 82008209.
  • Sharma, A.K., Sharma, A., Desai, D., Madhunapantula, S.V., Huh, S.J., Robertson, G.P., and Amin, S. (2008). Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates. J. Med. Chem. 51, 78207826.
  • Shida, D., Takabe, K., Kapitonov, D., Milstien, S., and Spiegel, S. (2008). Targeting SphK1 as a new strategy against cancer. Curr. Drug Targets 9, 662673.
  • Shin, J.H., Choi, G.S., Kang, W.H., and Myung, K.B. (2007). Sphingosine 1-phosphate triggers apoptotic signal for B16 melanoma cells via ERK and caspase activation. J. Korean Med. Sci. 22, 298304.
  • Shin, S.S., Wall, B.A., Goydos, J.S., and Chen, S. (2010). Akt2 is a downstream target of metabotropic glutamate receptor 1 (Grm1). Pigment Cell Melanoma Res. 23, 103111.
  • Singh, M., Lin, J., Hocker, T.L., and Tsao, H. (2008). Genetics of melanoma tumorigenesis. Br. J. Dermatol. 158, 1521.
  • Sinnberg, T., Lasithiotakis, K., Niessner, H. et al. (2009). Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J. Invest. Dermatol. 129, 15001515.
  • Smalley, K.S., and Herlyn, M. (2006). Towards the targeted therapy of melanoma. Mini Rev. Med. Chem. 6, 387393.
  • Smalley, K.S., Haass, N.K., Brafford, P.A., Lioni, M., Flaherty, K.T., and Herlyn, M. (2006). Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther. 5, 11361144.
  • Solit, D.B., and Rosen, N. (2011). Resistance to BRAF inhibition in melanomas. N. Engl. J. Med. 364, 772774.
  • Song, L., Xiong, H., Li, M., Liao, W.T., Wang, L., and Wu, J. (2011). Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-{kappa}B pathway in human non-small cell lung cancer. Clin. Cancer Res. 17, 18391849.
  • Spiegel, S., and Milstien, S. (2003). Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. 4, 397407.
  • Stahl, J.M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J.Q., Bosenberg, M.W., Kester, M., Sandirasegarane, L., and Robertson, G.P. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64, 70027010.
  • Tran, M.A., Gowda, R., Sharma, A., Park, E.J., Adair, J., Kester, M., Smith, N.B., and Robertson, G.P. (2008a). Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res. 68, 76387649.
  • Tran, M.A., Smith, C.D., Kester, M., and Robertson, G.P. (2008b). Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin. Cancer Res. 14, 35713581.
  • Tuveson, D.A., Weber, B.L., and Herlyn, M. (2003). BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4, 9598.
  • Vadas, M., Xia, P., McCaughan, G., and Gamble, J. (2008). The role of sphingosine kinase 1 in cancer: oncogene or non-oncogene addiction? Biochim. Biophys. Acta 1781, 442447.
  • Wijesinghe, D.S., Allegood, J.C., Gentile, L.B., Fox, T.E., Kester, M., and Chalfant, C.E. (2010). Use of high performance liquid chromatography-electrospray ionization-tandem mass spectrometry for the analysis of ceramide-1-phosphate levels. J. Lipid Res. 51, 641651.
  • Xia, P., Gamble, J.R., Wang, L., Pitson, S.M., Moretti, P.A., Wattenberg, B.W., D’Andrea, R.J., and Vadas, M.A. (2000). An oncogenic role of sphingosine kinase. Curr. Biol. 10, 15271530.